LMBA02 Protocol for Patients With a Burkitt Lymphoma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00180882
Verified September 2006 by Gustave Roussy, Cancer Campus, Grand Paris. Recruitment status was: Recruiting
To explore in a multicenter international prospective randomized study (phase III) whether rituximab combined with the standard French LMB chemotherapy scheme results in a higher rate of EFS than the LMB chemotherapy scheme alone in patients older than 18 years with Burkitt lymphoma or ALL 3.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Age : 18 years or older
Histologically or cytologically proven Burkitt lymphoma according to the WHO classification
WHO performance < 3
Known HIV positive infection
Positive serology for HCV and HBV (except after vaccination)
Patients previously treated for lymphoma
cardiac disease that contradict anthracycline chemotherapy
Psychological or psychiatric condition who contradict steroids therapy
Patients with serious renal failure unrelated to the lymphoma (serum creatinin level higher than 150 mmole/L)
Cirrhosis or severe hepatic failure unrelated to the lymphoma
Previous malignant disease except basal cell skin carcinoma or in situ uterine cervix carcinoma
Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
Primary organ transplant or other immunosuppressive conditions Pregnancy